Blog

European HealthTech, MedTech, and clinical AI have seen key updates across regulatory execution, deep-tech venture funding, and clinical integration: &nbsp;&nbsp; Venture Funding &amp; Deep Tech Rounds &nbsp;&nbsp; Xeltis (Netherlands): Secured €20.5M to advance its restorative vascular implants and polymer-based tissue engineering platform.Qureight (UK): Closed a $20M Series B to expand its AI-powered imaging infrastructure, focusing on lung and cardiac disease progression modelling in clinical trials.Onalabs (Spain): Raised €9.3M Series A for its non-invasive sweat-sensing wearables that offer continuous biomarker monitoring.Ahead Health (Switzerland): Secured €8.7M to scale preventative full-body MRI scanning integrated with automated diagnostic screening across Germany and the Netherlands.Azalea Vision (Belgium): Landed €7.5M in EIC funding for smart contact lens technology combining bio-sensing and embedded micro-optics.Regulatory Milestones &amp; Policy &nbsp;&nbsp; EU AI Act Oversight: Following the initial enforcement rollout for general transparency provisions, national authorities and the European AI Board are progressing with their first formal supervisory and auditing checks.MDR/IVDR &amp; AI Alignment: AI-enabled medical devices maintain their direct path under MDR/IVDR certification following the recent Digital Omnibus timeline adjustments, giving manufacturers a defined compliance runway before overlapping AI Act rules take effect.UK MHRA International Reliance: The UK published updated guidance on fast-track recognition pathways, allowing manufacturers to leverage prior FDA, Health Canada, and TGA approvals to accelerate market entry into Great Britain.Hospital Infrastructure &amp; Deployment Hospital-at-Home Expansion: Healthcare systems in the Nordics, France, and Germany expanded regional pilots for predictive remote patient monitoring (RPM), targeting post-discharge surgical care and heart failure prevention.Innovative Health Initiative (IHI): The EU consortium launched new funding calls focused on large-scale AI Foundation Toxicology Models to replace animal testing in preclinical safety evaluations. &nbsp;&nbsp; &gt;&gt;&gt;&gt; &nbsp;&nbsp; European Health AI developments this week centre on diagnostic AI funding, regulatory supervision and provider infrastructure rollouts: Funding &amp; Commercial Milestones TidalSense (UK): Raised £16 million to accelerate European and US commercialisation of its AI-powered diagnostic hardware/software platform for rapid chronic obstructive pulmonary disease (COPD) detection.Qureight (UK): Closed a $20 million Series B to scale its clinical trial image-analysis infrastructure, modelling complex lung and cardiac disease progression directly inside biopharma R&amp;D pipelines.Ahead Health (Switzerland): Secured €8.7 million and launched across Germany and the Netherlands, scaling preventive full-body MRI screening paired with automated diagnostic AI algorithms.EU Regulatory Enforcement &amp; Compliance AI Act Transparency Supervision: European national authorities and the European AI Office have begun formal oversight of transparency rules. Health systems and conversational triage providers now face mandatory clear-disclosure rules for patient-facing chatbots and synthetic/generative outputs.MDR/IVDR Grace Window: MedTech compliance software providers report increased traction navigating the transition phase, as the Digital Omnibus timeline adjustments defer high-risk AI medical device obligations under the AI Act to 2028, keeping current certification exclusively under MDR/IVDR.UK MHRA International Reliance: The UK regulator finalised draft pathways allowing accelerated Great Britain approvals by recognising prior clearances from the US FDA, Health Canada, and Australia’s TGA.Clinical &amp; Health System Deployment NHS Ambient Clinical Scribes: UK Trusts accelerated pilot rollouts for ambient voice technology (AVT) under NHS digital modernisation allocations, reducing administrative burden for general practitioners and hospital triage.Radiology AI Consolidation: European hospital networks expanded procurement of multi-modal diagnostic suites over point solutions, driven by recent consolidation across European diagnostic imaging vendors. &nbsp;&nbsp; &gt;&gt;&gt;&gt; &nbsp;&nbsp; Major European MedTech developments this week highlight clinical-grade hardware funding, regulatory clarity on conformity assessments, and regional health technology assessment (HTA) approvals: &nbsp;&nbsp; Hardware &amp; Clinical Diagnostics Funding &nbsp;&nbsp; Xeltis (Netherlands): Secured €20.5 million to advance its restorative bio-absorbable vascular implants, moving its synthetic polymer-based tissue engineering further along clinical development pipelines.Onalabs (Spain): Raised €9.3 million Series A to accelerate commercialisation of its non-invasive sweat-sensing wearables that provide continuous biomarker monitoring for chronic illness and inpatient telemetry.EVERSION (Germany): Closed a €2.3 million Seed round for its sensor-equipped, intelligent insole platform designed to diagnose and treat musculoskeletal and orthopaedic conditions.Regulatory Policy &amp; Market Access EU Notified Body Assessment Reforms: Industry analysis outlined key operational impacts of upcoming European Commission rules aimed at conformity assessments. The provisions establish maximum time caps across notified body review stages and require transparent, itemized cost quotes to reduce budget and scheduling bottlenecks for device makers.UK MHRA International Reliance Model: The MHRA advanced draft regulations creating an accelerated approval route into Great Britain. The pathway enables medical device manufacturers to leverage existing clearances from the US FDA, Health Canada, and Australia’s TGA to speed up UK market access.Tariff Protections under EU–US Trade Framework: Industry body MedTech Europe welcomed the formal adoption of EU legislative measures executing transatlantic tariff relief, stabilising cross-border supply chains for medical device components and surgical systems.&nbsp; Regional Health Technology Assessments (HTA) &nbsp; Tuscany Regional Health Authority (Italy): Published favourable rapid HTA procurement decisions under Regional Decree No. 17185, approving regional adoption for the ProACT adjustable male urinary incontinence prosthesis and the H1 HIP cementless ceramic on- ceramic resurfacing prosthesis for early-stage osteoarthritis. &nbsp;&nbsp; Nelson Advisors &gt; European HealthTech, MedTech, Digital Health Investment Banking &nbsp; Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk &nbsp;&nbsp; Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis &amp; predictions @ https://www.healthcare.digital&nbsp; Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb&nbsp; Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics&nbsp; &nbsp;&nbsp; Nelson Advisors LLP &nbsp; Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT &nbsp;&nbsp; <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a><a href="mailto:paul@nelsonadvisors.co.uk">paul@nelsonadvisors.co.uk</a>Meet Nelson Advisors @ 2026 Events &nbsp; Digital Health Rewired &gt; March 2026 &gt; Birmingham, UK&nbsp; &nbsp; NHS ConfedExpo &nbsp;&gt; June 2026 &gt; Manchester, UK&nbsp; &nbsp;&nbsp; HLTH Europe &gt; June 2026, Amsterdam, Netherlands &nbsp;&nbsp; HIMSS AI in Healthcare &gt; July 2026, New York, USA &nbsp; &nbsp; Bits &amp; Pretzels &gt; September 2026, Munich, Germany &nbsp; &nbsp;&nbsp; World Health Summit 2026 &gt; October 2026, Berlin, Germany &nbsp; &nbsp;HealthInvestor Healthcare Summit &gt; October 2026, London, UK&nbsp; HLTH USA 2026 &gt; October 2026, USA&nbsp; &nbsp; Barclays Health Elevate &gt; October 2026, London, UK&nbsp; &nbsp; Web Summit 2026 &gt; November 2026, Lisbon, Portugal &nbsp; &nbsp; MEDICA 2026 &gt; November 2026, Düsseldorf, Germany &nbsp; Venture Capital World Summit &gt; December 2026 Toronto, Canada

Nelson Advisors: This Week in European HealthTech, MedTech and Health AI: 21st August 2026

Nelson Advisors partners Lloyd Price and Paul Hemings were interviewed by Mergermarket for their 'Electronic patient record asset owners mull exits as AI potential grows story.' &nbsp;&nbsp; Source: <a href="https://mergermarket.ionanalytics.com/content/1004530343?source=news">https://mergermarket.ionanalytics.com/content/1004530343?source=news</a>Strategics and sponsors are considering exits from electronic patient record (EPR) holdings as artificial intelligence (AI) promises to disrupt the market. &nbsp; In the UK, CVC Capital Partners appointed Arma Partners to find a buyer for System C, one of the country's leading NHS software providers, as reported. Meanwhile, UnitedHealth Group sold its subsidiary Optum UK, including the healthcare software firm EMIS, to TPG, according to UnitedHealth's earnings report. &nbsp;&nbsp; Outside EMEA, sponsors TA Associates and GI Partners are looking to sell US software companyNetsmart Technologies for the second time in two years, as reported. And research by TD Cowen suggested that Oracle is considering offloading the EPR vendor Cerner, per multiple news outlets. &nbsp;&nbsp; Exit attempts this year may reflect efforts to secure a good return amid a broad downturn in valuations in the Software as a Service (SaaS) space driven by increasing AI competition, known as the “SaaSpocalypse”, said Lloyd Price, partner and co-founder at Nelson Advisors. &nbsp;&nbsp; In the long term, however, EPR providers are also likely to benefit from investor interest in AI because they hold high-quality patient data to feed models, data that is unavailable to competitors, Price said. The readiness to sell EPR assets right now could even be surprising, giventheir huge potential in AI, he added. &nbsp; Another factor in the favour of EPR vendors is that multi-year deals with healthcare providers provide high revenue visibility for buyers, according to Price and Reece Donovan, CEO of EPR specialist Mayden. "It can take a long time to earn trust and build confidence with our customers, but once you have done this it tends to lead to successful, longer-term relationships," Donovan said. &nbsp;&nbsp; "In terms of the capital available, this is certainly the right time to exit an asset like System C and similar assets," said a sector advisor, adding that there is an increasing number of fundraisings in the space. "We have tons of conversations with owners now." &nbsp;&nbsp; Likely buyers in these cases include sponsors in Europe and North American strategics, the sectoradvisor said. Strategics, such as major EPR players or those in adjacent markets, may want to tap into the target's data or stop a rival from accessing it, Price said. &nbsp;&nbsp; Click here to subscribe to Mergermarket and read the story in full - Electronic patient record asset owners mull exits as AI potential grows <a href="https://mergermarket.ionanalytics.com/content/1004530343?source=news">https://mergermarket.ionanalytics.com/content/1004530343?source=news</a>

Nelson Advisors interviewed by Mergermarket: Electronic patient record asset owners mull exits as AI potential grows

Nelson Advisors has been invited to Speak at the Health AI Summit 2027 in California, USA on the 3rd abd 4th of March 2027.Source: <a href="https://www.health-ai-summit.com/">https://www.health-ai-summit.com/</a>Health AI Summit 2027 is where hospital digital leaders, clinical informaticians, AI developers, payers, and compliance advisors gather to move health AI from pilot to practice.Health AI is scaling faster than the systems built to validate and fund it. Ambient documentation, imaging, and clinical agents reach the bedside before proof of value, governance, and reimbursement catch up. Clinical, technology, and regulatory teams align around foundation models built for care, governance that assigns accountability, demonstrated financial return, and new AI billing codes.Key Themes for 2027&gt; Proving clinical and financial return across AI procurement decisionsExamine why executive teams require clinical outcomes and financial returns before clearing AI budgets and why discretionary spending keeps flowing to startups.&gt; Moving from ambient scribes to foundation models and clinical AI agents Explore how documentation tools are giving way to foundation models and clinical agents, and how much autonomy clinicians will accept in live workflows.&gt; Establishing AI governance and accountability across the enterprise Analyze how health systems allocate responsibility for AI safety, monitoring, and performance while federal agencies continue to reshape AI governance.&gt; Expanding AI from single-site pilots to full enterprise deployment Understand how health systems move beyond isolated pilots to system-wide rollout, from ambient documentation to imaging, without overwhelming clinical teams.&gt; &nbsp;Validating clinical AI from regulatory clearance to real-world outcomes Learn about peer-reviewed evidence, device clearance pathways, and reductions in documentation burden and burnout that prove AI is safe to deploy.&gt; Converting first-ever AI billing codes into sustainable reimbursement Know how new billing codes for AI-assisted services, payer coverage decisions, device oversight, and state transparency rules decide whether AI gets paid for.<a href="https://www.health-ai-summit.com/">https://www.health-ai-summit.com/</a>

Nelson Advisors invited to Speak at the Health AI Summit 2027

Something fundamental has changed in European healthcare technology venture capital and it is not simply a matter of more money or less money. The market that emerged from the 2022–2024 correction is structurally different from the one that preceded it: fewer companies are being funded, but the survivors are being funded harder; capital that once sprayed across hundreds of point solutions now concentrates in a handful of flagship rounds; and artificial intelligence has quietly moved from being a differentiator worth a premium to a threshold requirement without which a company struggles to get a meeting at all. &nbsp;&nbsp; For founders, investors and acquirers operating in European HealthTech, understanding this new shape of the market matters more than tracking any single quarterly funding figure. The headline numbers now tell contradictory stories depending on which slice you examine, European digital health funding in the first quarter of 2026 fell 44% year on year, yet first-half funding rose 60% over the same period. Both figures are accurate. Reconciling them is the key to understanding where this market is actually going. We examine the data behind European healthcare technology and digital health venture capital through 2025 and the first half of 2026, draws out the durable patterns beneath the quarterly noise and identifies the forward signals that will define the market into 2027.<a href="https://www.healthcare.digital/single-post/nelson-advisors-european-healthcare-technology-and-digital-health-venture-capital-trends-patterns">https://www.healthcare.digital/single-post/nelson-advisors-european-healthcare-technology-and-digital-health-venture-capital-trends-patterns</a>

Nelson Advisors: European Healthcare Technology and Digital Health Venture Capital Trends, Patterns and Future Market Signals

If 2025 was the year European HealthTech discovered artificial intelligence, and 2026 the year the market learned to price it, then 2027 will be the year the sector is forced to prove it. The froth has gone. What remains is a market that is smaller in deal count, larger in deal size and far more discriminating about what it funds, buys and deploys. Q1 2026 told the story in miniature: European digital health venture funding fell 44% year-on-year to $1.2 billion across just 67 deals, yet average round sizes climbed 8% to over $21 million. Fewer bets, bigger cheques, higher expectations. &nbsp;&nbsp; 2027 arrives with three structural forces converging at once. The EU AI Act's high-risk obligations begin to bite in earnest, with enforcement for standalone high-risk AI systems landing in December 2027. The European Health Data Space (EHDS) reaches its first major milestone in March 2027, when the key implementing acts are published and the secondary-use framework starts taking concrete shape. A wall of private capital, private equity dry powder, strategics flush from the GLP-1 boom and a cautiously reopening IPO window, is looking for somewhere to land in a sector where the number of genuinely scaled, profitable European assets remains stubbornly small. &nbsp;&nbsp; For founders, investors and providers, 2027 will not be a year of new narratives. It will be a year of execution against the narratives already in place. Below are our ten predictions for how that plays out.<a href="https://www.healthcare.digital/single-post/nelson-advisors-european-healthcare-technology-predictions-2027-what-can-founders-investors-and-pr">https://www.healthcare.digital/single-post/nelson-advisors-european-healthcare-technology-predictions-2027-what-can-founders-investors-and-pr</a>

Nelson Advisors European Healthcare Technology Predictions 2027: What can Founders, Investors and Providers expect in 2027?

Few technology contracts in the history of the NHS have generated as much interest, scrutiny and hostility as the Federated Data Platform. Awarded to Palantir Technologies in November 2023 with a headline value of up to £330 Million over seven years, the FDP was billed as the digital backbone that would finally join up the NHS's notoriously fragmented data estate.&nbsp; &nbsp;&nbsp; Nearly three years on, the platform is live in the majority of English acute trusts, NHS England is publishing quarterly benefits figures and yet the political temperature around the contract has never been higher. A cross-party committee of MPs has formally urged the government to walk away. The British Medical Association has instructed doctors to limit their engagement. And a break clause in spring 2027 has turned the second half of 2026 into a decision point that will shape NHS data infrastructure for a decade. &nbsp;&nbsp; We look at how we got here, where the FDP actually stands today and what the next eighteen months are likely to bring.Future: The Break Clause and the Battle for NHS Data Infrastructure &nbsp;&nbsp; Everything now converges on a single contractual mechanism. The FDP's initial three year term ends in spring 2027, and the government must actively decide whether to trigger the first extension. Ministers have said a decision will come "later this year", that is, in the second half of 2026.&nbsp; &nbsp;&nbsp; The Health and Social Care Committee wants the break clause exercised in February 2027 and has asked the Department of Health and Social Care to assess whether a replacement contractor could be onboarded by March 2027.&nbsp; &nbsp;&nbsp; Foxglove, 38 Degrees, Amnesty International and allied campaigns are running coordinated public pressure for exactly that outcome, with tens of thousands of signatories. &nbsp;&nbsp; Three scenarios are plausible. &nbsp;&nbsp; The first is continuation. Ripping out a platform that is live in 139 trusts, mid-way through an elective recovery programme the government has staked its health credibility on, is operationally daunting and politically risky in its own way. The NHS has a £24.9 Million Foundry transition and exit contract on the books, but an actual migration would consume management bandwidth the service does not have. If NHS England can stabilise the evidence base, the independent Imperial College Projects evaluation, a £700,000 contract running from March 2026 to 2029, is meant to do exactly that, ministers may conclude that the least bad option is to extend, extract better terms, and tighten governance around supplier access. The awkward wrinkle is timing: the break clause decision will land before the evaluation reports, meaning the government will decide the FDP's future without the independent evidence it commissioned to judge it. &nbsp;&nbsp; The second scenario is managed exit. The committee's letter matters because it reframes exit as responsible planning rather than ideological rupture, and it noted evidence that some trusts already run alternative systems that match or exceed FDP functionality. The Procurement Act 2023, live since February 2025, gives contracting authorities stronger KPI and transparency tools and is generally friendlier to challenger suppliers. An estimated 150 NHS data, intelligence and AI contracts worth around £400 Million expire within two years, creating a genuine market moment for UK-headquartered analytics vendors, systems integrators and interoperability specialists. A government keen to signal digital sovereignty, a theme gathering force across Europe as dependence on US technology firms becomes a strategic anxiety , might find an exit both substantively defensible and politically useful. Advocacy groups have moved beyond pure opposition into constructive territory: Medact's 2026 paper "Beyond Palantir's FDP" sketches what NHS-controlled, standards-based data infrastructure could look like, drawing on precedents such as OpenSAFELY, the secure analytics environment built on GP data during the pandemic that never moved patient records out of their existing systems. The existence of credible, publicly-articulated alternatives changes the political calculus: ministers can no longer claim there is no other way. &nbsp;&nbsp; For the health technology market, the stakes extend well beyond one contract. The FDP decision will set the tone for how the NHS buys strategic data infrastructure for years. An exit, or even a contested renewal, would validate the challenger ecosystem: UK and European analytics vendors, federated-learning and secure data environment specialists, and the systems integrators who would carry any migration. Investors have noticed, data infrastructure, interoperability and waiting-list optimisation have been among the more resilient corners of UK healthtech dealmaking through 2025 and 2026, precisely because demand is policy driven and durable regardless of which logo sits on the platform. Conversely, a clean extension would confirm the gravitational advantage of incumbency at national scale and likely accelerate consolidation among smaller vendors who conclude they cannot compete head-on for national infrastructure and must instead position as acquirable point solutions within someone else's stack. &nbsp;&nbsp; The third scenario, and perhaps most likely, is a fudge: a short extension paired with a re-procurement process, tougher contractual conditions on supplier access and IP, and a commitment to modular, standards-based architecture that reduces lock-in over time. The critique that the NHS is spending £330 Million on a subscription that leaves it with "no lasting software, intellectual property or internal capability" has cut through with MPs across parties and any continuation will likely have to answer it.Click here to read the report in full <a href="https://www.healthcare.digital/single-post/palantir-the-nhs-federated-data-platform-past-present-and-future">https://www.healthcare.digital/single-post/palantir-the-nhs-federated-data-platform-past-present-and-future</a>

Nelson Advisors

Blog

Nelson Advisors: This Week in European HealthTech, MedTec...

Nelson Advisors interviewed by Mergermarket: Electronic p...

Nelson Advisors invited to Speak at the Health AI Summit ...

Nelson Advisors: European Healthcare Technology and Digit...

Nelson Advisors European Healthcare Technology Prediction...

Palantir, the NHS, Federated Data Platform: Past, Present...